Novo Nordisk’s GLP-1 medication, Rybelsus, reduced major adverse cardiovascular events by 14% compared to a placebo in a phase 3 trial, the drugmaker said Oct. 21.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
Novo Nordisk's GLP-1 pill reduces cardiovascular events by 14%
